Key Patent Granted for ORAVEXX by United States Patent and Trademark Office

Modernizing the way medicines
are taken.

Focused on improving patient outcomes through our next generation drug delivery technology, the RITe™ Platform.
Rapid Infusion Technology™ (RITe) Platform
Extremely rapid disintegration. Enhanced absorption profiles. The RITe™ Platform is an advancement beyond the state-of-the-art in orally disintegrating and buccal tablet technologies, enabling a range of active ingredients to work quickly and efficiently in the body.
Explore our platform

RITe™ tablets disintegrate in less than 3 seconds, rapidly adhering to the absorption site and delivering an active ingredient through the tissue in your cheek.

  • Easy to take

    No water needed for RITe™ tablets

  • Fast action

    Effects felt in minutes

  • Enhanced bioavailability

    Same effects, lower dose

  • Patient experience icon

    Superior patient experience

    Addresses pain points of drug delivery

See all benefits
Our Lead Program: ORAVEXX™ (cannabidiol)

Introducing a non-addictive alternative to opioids for the management of pain and inflammation

Learn more about ORAVEXX™
Proprietary Manufacturing

All RITe™ products are manufactured at our state-of-the-art cGMP-compliant facility in New Jersey.

Orcosa exclusively controls all applications of the RITe™ Platform, which utilizes custom machinery to enable seamless scaled manufacturing.
Learn more
Research

Collaborating with Leading Research Institutions

We are empowering the medical community by partnering with leading research institutions and physicians to support FDA-authorized investigator-initiated clinical trials that utilize the RITe™ Platform to independently evaluate the safety and efficacy of CBD for the management of pain and inflammation.
Explore the trials

News

Orcosa Appoints Kevin Kaplan, MD, as Chief Medical Officer

June 30, 2025 – EWING, N.J. – Orcosa Inc. (“Orcosa” or the “Company”), a clinical-stage life-sciences company improving patient outcomes through its next-generation drug-delivery technology – the Rapid Infusion Technology (RITe™) Platform – today announced the appointment of Kevin Kaplan, M.D., FAAOS, as Chief Medical Officer. In this role, Dr. Kaplan will direct clinical development, […]

Orcosa Chosen to Present at BioNJ’s BioPartnering Conference 2025

We are proud to share that Orcosa has been selected by BioNJ to present at the 2025 BioPartnering Conference on May 13th in Jersey City, NJ. Co-founder and COO, Vincent T. Mileto will deliver “Modernizing The Way Medicines Are Taken,” highlighting our RITe™ orally disintegrating tablet platform and its potential to transform drug delivery. “It’s […]

Orcosa Comments on Positive Results from One-Year Follow-Up Study to NYU Langone’s Phase 1/2 Clinical Trial Utilizing ORAVEXX™ for Acute Postoperative Pain

Ewing, NJ – February 5, 2024 – Orcosa Inc. (“Orcosa” or the “Company”), a life sciences company modernizing the way medicines are taken through its next generation drug delivery technology – the Rapid Infusion Technology (RITe™) Platform – today announced positive results from a one-year follow-up study to the Phase 1/2 clinical trial utilizing Orcosa’s lead […]

Orcosa Announces Two New Appointments to Board of Directors 

EWING, N.J. – January 30, 2024 – Orcosa Inc. (“Orcosa” or the “Company”), a clinical-stage life sciences company improving patient outcomes through its next generation drug delivery technology – the Rapid Infusion Technology (RITe™) Platform – today announced the appointment of Edward A. Sturchio and Robert S. Radie to Orcosa’s Board of Directors, effective January […]

View all